Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 1465 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

REVIEW ARTICLE

Bromocriptine in type 2 diabetes mellitus

Shivaprasad C, Kalra Sanjay

Year : 2011| Volume: 15| Issue : 5 | Page no: 17-24

   This article has been cited by
 
1 Dopamine D2 receptor signaling modulates pancreatic beta cell circadian rhythms
Heather Wei,Rizaldy C. Zapata,Mariela Lopez-Valencia,Despoina Aslanoglou,Zachary J. Farino,Valerie Benner,Olivia Osborn,Zachary Freyberg,Michael J. McCarthy
Psychoneuroendocrinology. 2020; 113: 104551
[Pubmed]  [Google Scholar] [DOI]
2 Circadian-timed quick-release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus
Bindu Chamarthi,Aaron Vinik,Michael Ezrokhi,Anthony H. Cincotta
Endocrinology, Diabetes & Metabolism. 2019;
[Pubmed]  [Google Scholar] [DOI]
3 Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
Diana Grajales,Vitor Ferreira,Ángela M. Valverde
Cells. 2019; 8(11): 1336
[Pubmed]  [Google Scholar] [DOI]
4 Novel Trajectories of Bromocriptine Antidiabetic Action: Leptin-IL-6/ JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPAR-?/Adiponectin, Nrf2/PARP-1, and GLP-1
Enji Reda,Sherifa Hassaneen,Hanan S. El-Abhar
Frontiers in Pharmacology. 2018; 9
[Pubmed]  [Google Scholar] [DOI]
5 Dopamine D2 receptors and the circadian clock reciprocally mediate antipsychotic drug-induced metabolic disturbances
Zachary Freyberg,Michael J. McCarthy
npj Schizophrenia. 2017; 3(1)
[Pubmed]  [Google Scholar] [DOI]
6 Bromocriptine treatment at the end of lactation prevents hyperphagia, higher visceral fat and liver triglycerides in early-weaned rats at adulthood
Nayara Peixoto-Silva,Egberto G Moura,Janaine C Carvalho,Jéssica L Nobre,Fernanda T Quitete,Cintia R Pinheiro,Ana Paula Santos-Silva,Elaine de Oliveira,Patricia C Lisboa
Clinical and Experimental Pharmacology and Physiology. 2017; 44(4): 488
[Pubmed]  [Google Scholar] [DOI]
7 Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases
Alexander O Shpakov,Kira V Derkach,Lev M Berstein
Future Science OA. 2015; 1(3)
[Pubmed]  [Google Scholar] [DOI]
8 Effect of Bromocriptine on Insulin Resistance in Patients with PCO
Zivar Shirinpour,Bahman Ghaderian,Homeira Rashidi,Armaghan Moravej Aleali,Seyed Peyman Payami
Open Journal of Endocrine and Metabolic Diseases. 2014; 04(12): 253
[Pubmed]  [Google Scholar] [DOI]
9 Bromocriptine mesylate QR in treatment of Type 2 diabetes
George Grunberger
Diabetes Management. 2014; 4(2): 203
[Pubmed]  [Google Scholar] [DOI]
10 New therapies in the management of type 2 diabetes mellitus
TC Hardman,SW Dubrey
British Journal of Hospital Medicine. 2013; 74(4): 202
[Pubmed]  [Google Scholar] [DOI]
11 Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: A natural approach to complement pharmacotherapy in the management of diabetes
Isabelle M. E. Lacroix,Eunice C. Y. Li-Chan
Molecular Nutrition & Food Research. 2013; : n/a
[Pubmed]  [Google Scholar] [DOI]
12 An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans
Stefan Amisten,Albert Salehi,Patrik Rorsman,Peter M. Jones,Shanta J. Persaud
Pharmacology & Therapeutics. 2013; 139(3): 359
[Pubmed]  [Google Scholar] [DOI]

 

Read this article